Infection with the hepatitis C virus (HCV) is a global health concern, with an estimated 71 million people infected in 2015 and 400 000 deaths each year. [1][2][3][4][5][6][7][8][9][10] HCV is the leading cause of liver disease, and there is currently no vaccination available to protect against it. Drugs known as direct-acting antivirals (DAAs) have now been approved for children as young as 3 years old. HCV elimination techniques for children, on the other hand, have yet to be developed. [10][11][12][13][14][15][16][17][18][19][20][21] Estimates of paediatric prevalence are needed to aid in the scaling up of therapy and screening and testing approaches for this population. The prevalence of HCV in this unique community has not been adequately investigated. [2][3][4][5][6][7][8][9] In Western Europe, the prevalence is expected to be 1.5% to 3.5%, but barely 0.5% in the United Kingdom, with little information on the prevalence in low-income countries. [2][3][4][5][6][7][8][9][10] HCV infection raises the risk of morbidity and mortality, and it is the major cause of end-stage liver disease, cirrhosis and liver cancer in people all over the world. [18][19][20][21][22][23] Despite the fact that HCV infection seldom causes morbidity in children, the majority of HCV-infected children develop chronic HCV, putting them at risk for life-threatening liver disease. [9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] Furthermore, some research suggests that HCV has an impact on children's quality of life and behaviour, as cognitive function has been proven to be impaired, and families have reported greater levels of stress, both of which have a negative impact on family connections and well-being. [21][22][23][24][25][26][27] There are few statistics on the prevalence of HCV in children at the moment. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] The purpose of this study was to look at